$2.08
0.48%
Nasdaq, Oct 21, 04:00 pm EDT. Closed.
ISIN
US09203E1055
Symbol
BDTX

Black Diamond Therapeutics Inc Stock price

$2.08
+0.13 6.67% 1M
-1.07 33.97% 6M
-0.35 14.40% YTD
-1.88 47.47% 1Y
+0.04 1.96% 3Y
-6.05 74.42% 5Y
-37.40 94.73% 10Y
-37.40 94.73% 20Y
Nasdaq, Closing price Wed, Oct 21 2026
+0.01 0.48%
ISIN
US09203E1055
Symbol
BDTX
Industry

Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$118.9m
Enterprise Value
$8.4m
Net debt
positive
Cash
$110.5m
Shares outstanding
57.5m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
1.2
Financial Health
Equity Ratio
78.5%
Return on Equity
19.9%
ROCE
-47.5%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$6.1m | -
SBC as % of FCF
-
SBC Growth 1Y
-14.1%
Share Count Growth 1Y
1.0%
Shareholder Yield
-1.0%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-51.7m
EBIT
$-51.9m
Net Income
$-42.6m
Free Cash Flow | ex SBC
$-32.8m | $-39.0m
Growth
Revenue | estimate
-100.0% | -100.0%
EBITDA
-1,048.6%
EBIT
-1,115.7%
Net Income
-404.4%
Free Cash Flow
-280.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
12.0%
Employees
21
Rev per Employee
$3.3m

Black Diamond Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Black Diamond Therapeutics Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Black Diamond Therapeutics Inc forecast:

Buy
86%
Hold
14%

Black Diamond Therapeutics Inc Events

Upcoming Event
NOV
4
Q3 2026 Earnings Call
in 14 days
View Past Earnings Reaction

Financial data from Black Diamond Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
19% 19%
-
- Research and Development Expense 28 28
38% 38%
-
-52 -52
1,049% 1,049%
-
- Depreciation and Amortization 0.21 0.21
38% 38%
-
EBIT (Operating Income) EBIT -52 -52
1,116% 1,116%
-
Net Profit -43 -43
404% 404%
-

In millions USD.

Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Black Diamond Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
3 months ago
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today reported financial results for the seco...
Neutral
GlobeNewsWire
●
5 months ago
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on J...
Neutral
GlobeNewsWire
●
5 months ago
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor ...
More Black Diamond Therapeutics Inc News

Company Profile

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Head office United States
CEO Dr. Velleca
Employees 21
Founded 2014
Website www.blackdiamondtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today